The natural history of actinic keratosis: A systematic review

British Journal of Dermatology

Volumn 169, Issue 3, 2013, Pages 502-518

  Werner, R N ^a   Sammain, A ^a   Erdmann, R ^a   Hartmann, V ^a   Stockfleth, E ^a   Nast, A ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

SUNSCREEN;

ACTINIC KERATOSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MEDICAL HISTORY; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REMISSION; REVIEW; RISK ASSESSMENT; SKIN CANCER; SKIN DEFECT; SYSTEMATIC REVIEW;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; EPIDEMIOLOGIC METHODS; HUMANS; IMMUNOSUPPRESSION; KERATOSIS, ACTINIC; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM REGRESSION, SPONTANEOUS; ORGAN TRANSPLANTATION; RISK FACTORS; SKIN NEOPLASMS;

EID: 84883352148     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12420     Document Type: Review

References (38)

1. Dubreuilh WA,. Des hyperkeratosis circonscrites. Ann Dermatol Venereol 1896; 27: 1158-64.
2. Heaphy MR Jr, Ackerman AB,. The nature of solar keratosis: a critical review in historical perspective. J Am Acad Dermatol 2000; 43: 138-50.
3. Ackerman AB, Mones JM,. Solar (actinic) keratosis is squamous cell carcinoma. Br J Dermatol 2006; 155: 9-22.
4. Feldman SR, Fleischer AB Jr,. Progression of actinic keratosis to squamous cell carcinoma revisited: clinical and treatment implications. Cutis 2011; 87: 201-7.
5. Rigel DS, Stein Gold LF,. The importance of early diagnosis and treatment of actinic keratosis. J Am Acad Dermatol 2013; 68: S20-7.
6. Cockerell CJ,. Histopathology of incipient intraepidermal squamous cell carcinoma ('actinic keratosis'). J Am Acad Dermatol 2000; 42: 11-7.
7. Röwert-Huber J, Patel MJ, Forschner T, et al,. Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol 2007; 156: 8-12.
8. Ra SH, Li X, Binder S,. Molecular discrimination of cutaneous squamous cell carcinoma from actinic keratosis and normal skin. Mod Pathol 2011; 24: 963-73.
9. Moher D, Liberati A, Tetzlaff J, et al,. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535.
10. Alberts DS, Dorr RT, Einspahr JG, et al,. Chemoprevention of human actinic keratoses by topical 2-(difluoromethyl)- dl -ornithine. Cancer Epidemiol Biomarkers Prev 2000; 9: 1281-6.
11. Alirezai M, Dupuy P, Amblard P, et al,. Clinical evaluation of topical isotretinoin in the treatment of actinic keratoses. J Am Acad Dermatol 1994; 30: 447-51.
12. Criscione VD, Weinstock MA, Naylor MF, et al,. Actinic keratoses: natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer 2009; 115: 2523-30.
13. Darlington S, Williams G, Neale R, et al,. A randomized controlled trial to assess sunscreen application and beta carotene supplementation in the prevention of solar keratoses. Arch Dermatol 2003; 139: 451-5.
14. Elmets CA, Viner JL, Pentland AP, et al,. Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst 2010; 102: 1835-44.
15. Foote JA, Ranger-Moore JR, Einspahr JG, et al,. Chemoprevention of human actinic keratoses by topical dl -alpha-tocopherol. Cancer Prev Res (Phila) 2009; 2: 394-400.
16. Frost C, Williams G, Green A,. High incidence and regression rates of solar keratoses in a Queensland community. J Invest Dermatol 2000; 115: 273-7.
17. Green C, Orchard G, Cerio R, Hawk JL,. A clinicopathological study of the effects of topical retinyl propionate cream in skin photoageing. Clin Exp Dermatol 1998; 23: 162-7.
18. Harvey I, Frankel S, Marks R, et al,. Non-melanoma skin cancer and solar keratoses. I. Methods and descriptive results of the South Wales Skin Cancer Study. Br J Cancer 1996; 74: 1302-7.
19. Jorizzo J, Dinehart S, Matheson R, et al,. Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. J Am Acad Dermatol 2007; 57: 265-8.
20. Korman N, Moy R, Ling M, et al,. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials. Arch Dermatol 2005; 141: 467-73.
21. Marks R, Foley P, Goodman G, et al,. Spontaneous remission of solar keratoses: the case for conservative management. Br J Dermatol 1986; 115: 649-55.
22. Marks R, Rennie G, Selwood TS,. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet 1988; 1: 795-7.
23. Moloney F, Vestergaard M, Radojkovic B, Damian D,. Randomized, double-blinded, placebo-controlled study to assess the effect of topical 1% nicotinamide on actinic keratoses. Br J Dermatol 2010; 162: 1138-9.
24. Stockfleth E, Zwingers T, Willers C,. Recurrence rates and patient assessed outcomes of 0.5% 5-fluorouracil in combination with salicylic acid treating actinic keratoses. Eur J Dermatol 2012; 22: 370-4.
25. Szeimies RM, Stockfleth E, Popp G, et al,. Long-term follow-up of photodynamic therapy with a self-adhesive 5-aminolaevulinic acid patch: 12 months data. Br J Dermatol 2010; 162: 410-4.
26. Szeimies RM, Gerritsen MJ, Gupta G, et al,. Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J Am Acad Dermatol 2004; 51: 547-55.
27. Thompson SC, Jolley D, Marks R,. Reduction of solar keratoses by regular sunscreen use. N Engl J Med 1993; 329: 1147-51.
28. Ulrich C, Bichel J, Euvrard S, et al,. Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. Br J Dermatol 2007; 157 (Suppl. 2): 25-31.
29. Ulrich C, Jurgensen JS, Degen A, et al,. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol 2009; 161 (Suppl. 3): 78-84.
30. Wulf HC, Pavel S, Stender I, Bakker-Wensveen CA,. Topical photodynamic therapy for prevention of new skin lesions in renal transplant recipients. Acta Derm Venereol 2006; 86: 25-8.
31. Cantrell W, Turnham JW, Andea AA, et al,. Actinic keratoses are intermittently present during the natural course of their disease. J Invest Dermatol 2009; 129: S53.
32. Kang S, Goldfarb MT, Weiss JS, et al,. Assessment of adapalene gel for the treatment of actinic keratoses and lentigines: a randomized trial. J Am Acad Dermatol 2003; 49: 83-90.
33. Zeichner JA, Stern DWK, Uliasz A, et al,. Placebo-controlled, double-blind, randomized pilot study of imiquimod 5% cream applied once per week for 6 months for the treatment of actinic keratoses. J Am Acad Dermatol 2009; 60: 59-62.
34. Epstein E,. Quantifying actinic keratosis: assessing the evidence. Am J Clin Dermatol 2004; 5: 141-4.
35. Weinstock MA, Bingham SF, Cole GW, et al,. Reliability of counting actinic keratoses before and after brief consensus discussion: the VA topical tretinoin chemoprevention (VATTC) trial. Arch Dermatol 2001; 137: 1055-8.
36. Bradburn MJ, Deeks JJ, Berlin JA,. Russell Localio A. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 2007; 26: 53-77.
37. Green A, Williams G, Neale R, et al,. Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomised controlled trial. Lancet 1999; 354: 723-9.
38. Hauschild A, Stockfleth E, Popp G, et al,. Optimization of photodynamic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: results of two randomized controlled phase III studies. Br J Dermatol 2009; 160: 1066-74.